

Quinidine (502): sc-57991

BACKGROUND

Quinidine is a class I antiarrhythmic agent first obtained from the bark of the *Cinchona* tree. It is a stereoisomer of quinine that functions by blocking the fast inward sodium current, causing the phase 0 depolarization of the cardiac action potential to decrease and prolonging the cardiac action potential, thereby prolonging the QT interval on the surface EKG. Quinidine also blocks the slowly inactivating tetrodotoxin-sensitive sodium current, the slow inward calcium current, the rapid and slow components of the delayed potassium rectifier current, the inward potassium rectifier current and the ATP-sensitive potassium channel. Quinidine inhibits the cytochrome P450 enzyme 2D6, and it may lead to increased blood levels of lidocaine, β blockers, opioids and some antidepressants. Quinidine has a half life of six to eight hours, a molecular weight of 324.417 g/mol and is metabolized in the liver by the cytochrome P450 system.

REFERENCES

1. Yeh, J.Z. and Narahashi, T. 1976. Mechanism of action of Quinidine on squid axon membranes. *J. Pharmacol. Exp. Ther.* 196: 62-70.
2. Salata, J.J. and Wasserstrom, J.A. 1988. Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. *Circ. Res.* 62: 324-337.
3. Nattel, S. and Quantz, M.A. 1989. Pharmacological response of Quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. *Cardiovasc. Res.* 22: 808-817.
4. Undrovinas, A.I., Burnashev, N., Eroshenko, D., Fleidervish, I., Starmer, C.F., Makielski, J.C. and Rosenshtraukh, L.V. 1990. Quinidine blocks adenosine 5'-triphosphate-sensitive potassium channels in heart. *Am. J. Physiol.* 259: H1609-1612.
5. von Moltke, L.L., Greenblatt, D.J., Cotreau-Bibbo, M.M., Harmatz, J.S. and Shader, R.I. 1994. Inhibitors of alprazolam metabolism *in vitro*: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and Quinidine. *Br. J. Clin. Pharmacol.* 38: 23-31.
6. Anyukhovsky, E.P., Sosunov, E.A., Feinmark, S.J. and Rosen, M.R. 1998. Effects of Quinidine on repolarization in canine epicardium, midmyocardium and endocardium: II. *In vivo* study. *Circulation* 96: 4019-4026.
7. Darbar, D., Fromm, M.F., Dellorto, S. and Roden, D.M. 2001. Sympathetic activation enhances QT prolongation by Quinidine. *J. Cardiovasc. Electrophysiol.* 12: 9-14.
8. Mathis, A.S. and Gandhi, A.J. 2002. Serum Quinidine concentrations and effect on QT dispersion and interval. *Ann. Pharmacother.* 36: 1156-1161.
9. Appel, S.B., Liu, Z., McElvain, M.A. and Brodie, M.S. 2003. Ethanol excitation of dopaminergic ventral tegmental area neurons is blocked by Quinidine. *J. Pharmacol. Exp. Ther.* 306: 437-446.

SOURCE

Quinidine (502) is a mouse monoclonal antibody raised against Quinidine.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 100 μ g IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Quinidine (502) is recommended for detection of Quinidine by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.